Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...

Eisai and Biogen have completed their rolling biologics ... Meanwhile, the partners have also filed to extend the label for Leqembi to include a new maintenance dosing regimen that would reduce ...

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu. It seems Eisai and Biogen have another hurdle ...

Chappell Roan called out the record labels during her acceptance speech at the 2025 Grammy Awards. The singer took the stage at the Crypto.com Arena in Los Angeles to accept her first Grammy after ...

Chappell Roan won the Grammy Award for best new artist, and used her moment to speak out for all struggling artists. The “Pink Pony Club” singer took the stage holding a notebook where she ...